Effects of Hypertonic Saline-HES Solution on Extracellular Water in Cardiac Surgery Patients
Effects of Hypertonic Saline-hydroxyethyl Starch Solution on Extracellular Water in Cardiac Surgery Patients
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Cardiac surgery and cardiopulmonary bypass (CPB) cause fluid retention in the body. Both dilution of serum proteins and destruction of vascular endothelial glycocalyx cause extravasation of the fluids. We cannot avoid this phenomenon but we can try to restore the excess fluid into the intravascular space where it can be excreted via the kidneys.
Hypertonic saline (HS) creates an osmotic gradient across the cellular membrane, causing a fluid shift from the intracellular space into the extracellular space and from the extravascular space into the intravascular space. The intravascular hypertonic benefit is short-lasting as a result of redistribution of fluid between the intravascular and interstitial spaces. The effect can be lengthened by adding colloid component into the solution.
The aim of the study is to describe the effects of hypertonic saline/hydroxyethylstarch solution in comparison to saline solution for 25 + 25 patients undergoing coronary bypass grafting surgery (CABG) using CPB. The study fluid will be given into the venous reservoir of the CPB circuit after aortic declamping. Primary endpoints are the changes in body weight and extracellular water from baseline to the first postoperative morning. Secondary endpoints are the need of fluids and diuretic medication during the perioperative period.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Tampere, Finland, 33521
- Tampere University Hospital Heart Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- male gender and no need for pulmonary artery catheter (pulmonary hypertension or left ventricular ejection fraction < 40%).
Exclusion Criteria:
- chronic hyponatremia and significant renal dysfunction.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: 7.2% NaCl/hydroxyethyl starch
250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)
|
250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
Andre navne:
|
|
Aktiv komparator: 0.9% NaCl
250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)
|
250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in extracellular water from baseline to the first postoperative morning.
Tidsramme: 24h
|
Perioperative fluid balance will be assessed by measuring changes in body weight and extracellular water from baseline to the first postoperative morning.
|
24h
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Need of fluids during the day of surgery.
Tidsramme: 24h
|
Need of fluids and diuretic medication during the day of surgery until the first postoperative morning will be recorded.
|
24h
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Kati Järvelä, MD, PhD, Tampere University Hospital Heart Center
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- R09246M
- 2010-019352-42 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Væskevolumenforstyrrelse
-
European Society of Intensive Care MedicineAfsluttet
-
CHU de ReimsIkke rekrutterer endnuFluid reaktionsevne i tidlig transplantationsperiode efter KidneyFrankrig
Kliniske forsøg med 7.2% NaCl/hydroxyethylstarch
-
Medtronic - MITGAfsluttetLungekræftForenede Stater
-
The Hospital for Sick ChildrenAfsluttet
-
Radboud University Medical CenterExponential Biotherapies Inc.UkendtSystemisk inflammatorisk responssyndrom | Koronararterie-bypass-transplantationHolland
-
Carmel Medical CenterUkendt
-
DLR German Aerospace CenterCharite University, Berlin, Germany; University of Erlangen-NürnbergAfsluttet
-
Ahmad Jabir RahyussalimUkendtMesenkymal stamcelle | Spinal tuberkuloseIndonesien
-
Phramongkutklao College of Medicine and HospitalUkendt
-
Tianjin Medical University General HospitalCangzhou Hospital of Integrated Traditional Chinese and Western Medicine og andre samarbejdspartnereAfsluttet
-
Hamilton Health Sciences CorporationAfsluttet
-
Aydin Adnan Menderes UniversityAfsluttetPostoperativ kvalme og opkastningKalkun